Dynavax delivered robust Q2 2025 results, achieving record quarterly net product revenue for HEPLISAV-B of $91.9 million, a 31% increase year-over-year. The company reported a GAAP net income of $18.7 million and an EPS of $0.14 diluted. HEPLISAV-B's U.S. market share increased to approximately 45%.

Dynavax reported a strong first quarter in 2025, achieving its highest first quarter net product revenue for HEPLISAV-B to date, with total revenues increasing by 34% year-over-year. The company also made significant progress in its pipeline, with key clinical trial milestones for shingles and plague vaccine programs, and new programs in pandemic influenza and Lyme disease entering clinical development.

Dynavax achieved record HEPLISAV-B product revenue in 2024 and continued to advance its pipeline programs. The company reported a 30% increase in total revenues for Q4 2024 compared to Q4 2023, and a significant increase in adjusted EBITDA year-over-year.

Dynavax reported a 16% year-over-year increase in total revenues, reaching $80.6 million, with HEPLISAV-B net product revenue growing by 27% to $79.3 million. The company's net income was $17.6 million, or $0.13 per share basic and $0.12 diluted. They also announced a $200 million share repurchase program and discontinued the Tdap-1018 program to focus on long-term value creation.

Dynavax reported a strong second quarter in 2024, marked by record HEPLISAV-B net product revenue and the initiation of a Phase 1/2 trial for its novel shingles vaccine program. The company is optimistic about the adult hepatitis B vaccine market and continues to evaluate strategic opportunities for growth.

Dynavax reported a 10% year-over-year growth in HEPLISAV-B net product revenue, reaching $47.8 million in Q1 2024. The company is reaffirming its full-year 2024 HEPLISAV-B net product revenue guidance of $265 - $280 million. The U.S. FDA cleared the IND application to initiate a Phase 1/2 trial of the Z-1018 shingles program.

Dynavax reported HEPLISAV-B vaccine net product revenue of $51.1 million for Q4 2023, a 46% increase compared to Q4 2022. The company's cash position increased to $742.3 million at year-end and anticipates being cash flow positive for the full year 2024. They expect 2024 to be an important year in building a vaccine portfolio of best-in-class products.

Dynavax reported a record quarter of HEPLISAV-B revenue, driven by market share growth and expansion of the adult hepatitis B market. The company is focused on advancing its pipeline of innovative vaccine candidates and pursuing strategic opportunities to accelerate growth. Full year HEPLISAV-B net product revenue guidance was raised to $210 - $220 million.

Dynavax reported total revenues of $60.2 million for the second quarter of 2023, including record HEPLISAV-B vaccine net product revenue of $56.4 million, a 73% year-over-year increase. The company raised its full year HEPLISAV-B net product revenue guidance to $200 - $215 million. Cash and investments increased to $682 million at quarter end.

Dynavax reported a first quarter 2023 total revenue of $46.9 million, which includes HEPLISAV-B vaccine product revenue of $43.5 million, a 109% increase compared to the first quarter of 2022. The company's cash and investments were $652 million at quarter end and expects positive free cash flow in 2023.

Dynavax reported a decrease in total revenue for the fourth quarter of 2022, with $184.5 million compared to $195.1 million for the fourth quarter of 2021. However, HEPLISAV-B vaccine product revenue increased to $34.9 million from $17.2 million in the same period.

Dynavax reported a successful Q3 2022 with a 55% increase in total revenue compared to Q3 2021, driven by strong performance of HEPLISAV-B and CpG 1018 adjuvant. The company is on track for a second consecutive year of profitability.

Dynavax reported strong second-quarter results, driven by significant growth in both HEPLISAV-B and CpG 1018 adjuvant revenues. The company is on track for another profitable year and is well-capitalized to invest in programs that drive revenue growth and advance its clinical pipeline.

Dynavax reported a strong start to 2022 with total revenue of $114.0 million, a 37% increase compared to Q1 2021. The company is on track for a second consecutive year of profitability, driven by growth in HEPLISAV-B vaccine and CpG 1018 adjuvant supply.

Dynavax reported record total revenue for 2021, driven by significant growth in CpG 1018 adjuvant and HEPLISAV-B sales. The company achieved its first profitable year and ended the year with a strong cash position, enabling investments in its pipeline.

Dynavax reported strong progress with HEPLISAV-B and CpG 1018 vaccine adjuvant platform in Q3 2021. Total revenue reached $108.3 million, driven by growth in HEPLISAV-B market share and revenue, along with positive data readouts for CpG 1018 adjuvanted COVID-19 vaccine candidates. The company ended the quarter with $414 million in cash and equivalents.

Dynavax reported a successful Q2 2021, marked by record HEPLISAV-B revenue of $13.7 million and significant CpG 1018 revenue of $39 million driven by multiple commercial supply agreements. The company achieved a net income of $4.5 million, a substantial improvement from the previous year's net loss.

Dynavax announced first quarter 2021 financial results with a total revenue of $83.3 million. The company's growth was driven by strong execution in the CpG 1018 adjuvant business and HEPLISAV-B market share growth.

Dynavax's Q4 2020 total revenues reached $19.6 million, including $13.1 million from net product revenue. The company experienced a net loss of $15.5 million, a decrease from the $36.8 million net loss in Q4 2019. Full year 2020 total revenue was $46.6 million, up from $35.2 million in 2019.

Dynavax reported a net income of $4.4 million for Q3 2020, a significant improvement compared to the net loss of $36.7 million in Q3 2019. The company's HEPLISAV-B net product revenue reached its highest since launch at $11.6 million, and initial CpG 1018 revenue and deferred revenue totaled $23.4 million.

Dynavax reported a net product revenue of $2.4 million for HEPLISAV-B in Q2 2020, which declined compared to $8.3 million in the same period in 2019 due to the COVID-19 pandemic. The company experienced a net loss of $51.6 million, which includes expense of $25.7 million due to an increase in the estimated fair value of outstanding warrants. Cash, cash equivalents and marketable securities totaled $200.7 million at June 30, 2020.

Dynavax Technologies Corporation reported first quarter 2020 financial results. HEPLISAV-B net product revenue was $10.5 million, compared to $5.6 million in Q1 2019. Net loss allocable for the first quarter of 2020 was $12.6 million, or $0.15 per basic share and $0.25 per diluted share, compared to a net loss of $39.7 million, or $0.62 per basic and diluted share, for the first quarter of 2019.

Dynavax's Q4 2019 earnings show a net product revenue of $10.6 million, a significant increase from $3.9 million in Q4 2018. The company's market share in targeted accounts also rose to 21% from 18% in the previous quarter. The net loss allocable to common stockholders was $36.8 million, or $0.44 per share.